Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Major Shareholder Announcement1 Oct 2007
Genmab's Total Number of Voting Rights and Total Share Capital28 Sept 2007
Major Shareholder Announcement28 Sept 2007
Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study27 Sept 2007
Articles of Association20 Sept 2007
Capital Increase in Genmab as a Result of Employee Warrant Exercise18 Sept 2007
DAHANCA Initiates Head and Neck Cancer Study with Genmab's HuMax-EGFr13 Sept 2007
Genmab Announces Asset Exchange Agreement
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
13 Sept 2007
Genmab Discloses Target and Development Plans for HuMax-Inflam13 Sept 2007
Genmab Provides Insights into IgG4 Antibodies13 Sept 2007
Genmab Announces Encouraging Preclinical Data for Ofatumumab7 Sept 2007
Genmab to Attend Three September Investor Conferences3 Sept 2007
  • Previous
  • 1
  • More pages
  • 117
  • 118
  • 119
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863